Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Solid Tumor Clinical Trial

Official title:

Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05037149
• Other study ID #: SRN-707-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: November 1, 2021
• Est. completion date: March 30, 2024

Study information

• Verified date: March 2024
• Source: Sirnaomics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.

Description:

A phase 1, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy. The primary objective of this study is to determine the MTD or RP2D of STP707 and to establish the dose of STP707 recommended for future phase 2 studies administered intravenously. A total of 30 subjects will be enrolled in dose escalation. Once MTD or RP2D has been established, up to 10 additional subjects will enrolled to confirm safety and explore anti-tumor activity. Up to 5 dose levels will be explored (3,6,12,24,48 mg dose levels). Intermediate doses between scheduled dose levels maybe explored during escalation. A cycle is 28 days. Dose escalation will follow a standard 3+3 design.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: March 30, 2024
• Est. primary completion date: March 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with histologically or cytologically confirmed advanced / metastatic or surgically unresectable solid tumors whose tumors are refractory to standard therapy

2. Measurable disease per RECIST v 1.1 (primary or metastatic disease)

3. ECOG performance status 0 - 1

4. Life expectancy of at least 3 months

5. Age =18 years

6. Signed, written Institutional Review Board (IRB) approved informed consent

7. A negative serum pregnancy test (for nonsterile women of child-bearing potential)

8. Acceptable liver function:

• Bilirubin = 1.5 times upper limit of normal
• AST (SGOT), ALT (SGPT) = 5 times upper limit of normal because of cancer or metastases to the liver

9. Acceptable renal function, defined as:

o Serum creatinine = 1.5 ULN or Creatinine Clearance = 50 mL/minute

10. Acceptable hematologic status:

• Hemoglobin = 9 g/dL (a transfusion is allowed if Hemoglobin stays stable thereafter)
• Absolute neutrophil count (ANC) = 1,000 cells/mm3
• Platelet count = 100,000 plt/mm3 x 109/ L

11. Urinalysis with no clinically significant abnormalities

12. Acceptable coagulation status with partial thromboplastin time (PTT) and International Normalized Ratio (INR) = 1.5 times upper limit of normal unless patient is on anticoagulants and has stable PTT and PT that are within normal therapeutic range for disease under management

13. Subject has adequate vitamin D level, as defined by serum total 25-Hydroxyvitamin D [25(OH)D] = 20 to < 60 ng/mL. If subjects are below this threshold, they may receive vitamin D supplementation se per clinic dosing guidelines and may still be enrolled provided they are started on vitamin D supplementation

14. Completion of all previous treatments (including surgery, systemic chemotherapy, and radiotherapy) at least 3 weeks before screening

15. For men and women of child-producing potential, the use of effective contraceptive methods during the study

Exclusion Criteria:

1. Baseline Q-T corrected interval (QTc) interval of > 470 msec for all subjects calculated using Fridericia's formula

2. New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months

3. Known active, uncontrolled infection with HIV or hepatitis B; subjects with hepatitis B allowed if on anti-viral therapy and have a viral load = 500 IU; patients with a history of HIV must be on antiretroviral therapy for at least four weeks and have an HIV viral load = 400 copies/mL, have CD4+ T cell counts = 350 cells/uL and no history of AIDS-defining opportunistic infections within 3 months prior to treatment

4. Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure, during the course of the study. (Note: Placement of a central venous access catheter(s) (e.g., port or similar) is not considered a major surgical procedure.)

5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.

6. Pregnant or nursing women. NOTE: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

7. Participation in a clinical study involving administration of an investigational compound within the past 30 days prior to study entry.

8. Unwillingness or inability to comply with procedures required in this protocol

9. Known allergy or hypersensitivity to the study drug(s) or one of the ingredients in the formulation (e.g., Trehalose dihydrate)

10. Existence of any surgical, medical or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism or excretion of the drug

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• STP707
STP707 Powder for Injection

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	NEXT Oncology	Austin	Texas
United States	Sarah Cannon Research Institute at HealthONE	Denver	Colorado
United States	Mayo Clinic	Jacksonville	Florida
United States	USC Norris Comprehensive Cancer Center	Los Angeles	California
United States	Atlantic Health System	Morristown	New Jersey
United States	Yale University	New Haven	Connecticut
United States	Mayo Clinic	Phoenix	Arizona
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Sirnaomics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)	Recommended starting dose & schedule	28 Day Cycle
Primary	Limited Dose Toxicity (LDT)	Recommended starting dose & dose escalation	28 day cycle